We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Eloxx Pharmaceuticals, Inc. has acquired Zikani Therapeutics, Inc. in an all-stock transaction, combines complementary ribosomal RNA-targeted genetic therapy platforms and therapies for the treatment of rare diseases and oncology.